

Marie-Christine Alessi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9061319/marie-christine-alessi-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

321 papers	20,337 citations	75 h-index	135 g-index
352 ext. papers	22,397 ext. citations	6.6 avg, IF	6.16 L-index

#	Paper	IF	Citations
321	On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 923-930	7	1
320	Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besançon). <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1186-1199	15.4	2
319	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1364-1371	15.4	3
318	Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates. <i>Blood</i> , 2021 , 137, 2256-2266	2.2	7
317	A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant. <i>PLoS Genetics</i> , 2021 , 17, e1009284	6	1
316	GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2287-2301	15.4	0
315	Atypical late diagnosis of Noonan syndrome revealed by bleedings due to platelet dysfunction. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 1	5.1	
314	Strengths and Weaknesses of Light Transmission Aggregometry in Diagnosing Hereditary Platelet Function Disorders. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	13
313	Contribution of exome sequencing to the identification of genes involved in the response to clopidogrel in cardiovascular patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1425-1434	15.4	1
312	Bernard-Soulier syndrome: first human case due to a homozygous deletion of GP9 gene. <i>British Journal of Haematology</i> , 2020 , 188, e87-e90	4.5	
311	RasGRP2 Structure, Function and Genetic Variants in Platelet Pathophysiology. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	9
310	An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group. <i>Pathology</i> , 2020 , 52, 243-255	1.6	11
309	Perioperative Open-lung Approach, Regional Ventilation, and Lung Injury in Cardiac Surgery. <i>Anesthesiology</i> , 2020 , 133, 1029-1045	4.3	11
308	High prevalence of mutations in perilipin 1 in patients with precocious acute coronary syndrome. <i>Atherosclerosis</i> , 2020 , 293, 86-91	3.1	0
307	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 732-739	15.4	32
306	Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach. <i>European Journal of Pharmacology</i> , 2020 , 866, 172798	5.3	6
305	A Combination of Single Nucleotide Polymorphisms is Associated with the Interindividual Variability of Cholesterol Bioavailability in Healthy Adult Males. <i>Molecular Nutrition and Food Research</i> , 2020 , 64, e2000480	5.9	2

304	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. <i>Blood</i> , 2020 , 136, 1956-1967	2.2	15
303	Laboratory Techniques Used to Diagnose Constitutional Platelet Dysfunction. <i>Hamostaseologie</i> , 2020 , 40, 444-459	1.9	2
302	Common Risk Factors Add to Inherited Thrombophilia to Predict Venous Thromboembolism Risk in Families. <i>TH Open</i> , 2019 , 3, e28-e35	2.7	6
301	Augmenting pharmacotherapy with neuromodulation techniques for the treatment of bipolar disorder: a focus on the effects of mood stabilizers on cortical excitability. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1575-1588	4	10
300	Thromboxane-prostaglandin receptor antagonist, terutroban, prevents neurovascular events after subarachnoid haemorrhage: a nanoSPECT study in rats. <i>Critical Care</i> , 2019 , 23, 42	10.8	6
299	Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation. <i>Scientific Reports</i> , 2019 , 9, 3750	4.9	5
298	Binding of Coagulation Factor XIII Zymogen to Activated Platelet Subpopulations: Roles of Integrin α IIb β 3 and Fibrinogen. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 906-915	7	6
297	A Novel Rapid Method of Red Blood Cell and Platelet Permeabilization and Staining for Flow Cytometry Analysis. <i>Cytometry Part B - Clinical Cytometry</i> , 2019 , 96, 426-435	3.4	5
296	Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2188-2195	15.4	3
295	Novel ACTN1 variants in cases of thrombocytopenia. <i>Human Mutation</i> , 2019 , 40, 2258-2269	4.7	3
294	Increased levels of the megakaryocyte and platelet expressed cysteine proteases stefin A and cystatin A prevent thrombosis. <i>Scientific Reports</i> , 2019 , 9, 9631	4.9	4
293	Platelet CD40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019 , 3, 684-694	5.1	4
292	Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia. <i>Endocrine Connections</i> , 2019 , 8, 349-359	3.5	2
291	Long-term management of leukocyte adhesion deficiency type III without hematopoietic stem cell transplantation. <i>Haematologica</i> , 2018 , 103, e264-e267	6.6	11
290	Anti- α IIb β 3 immunization in Glanzmann thrombasthenia: review of literature and treatment recommendations. <i>British Journal of Haematology</i> , 2018 , 181, 173-182	4.5	5
289	A new heterozygous mutation in GP1BA gene responsible for macrothrombocytopenia. <i>British Journal of Haematology</i> , 2018 , 183, 503-506	4.5	6
288	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia: A Network Analysis. <i>JAMA Psychiatry</i> , 2018 , 75, 396-404	14.5	114
287	Mutations of the integrin α IIb β 3 intracytoplasmic salt bridge cause macrothrombocytopenia and enlarged platelet δ granules. <i>American Journal of Hematology</i> , 2018 , 93, 195-204	7.1	12

286	Assessment of platelet function on the routine coagulation analyzer Sysmex CS-2000i. <i>Platelets</i> , 2018 , 29, 95-97	3.6	13
285	The Annexin A1 Receptor FPR2 Regulates the Endosomal Export of Influenza Virus. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	8
284	From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 7202-7217	8.3	24
283	Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections. <i>British Journal of Pharmacology</i> , 2018 , 175, 388-403	8.6	11
282	Clinical and Laboratory Findings in Patients with E-storage Pool Disease: A Case Series. <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 48-58	5.3	15
281	Modulation of T Cell Activation in Obesity. <i>Antioxidants and Redox Signaling</i> , 2017 , 26, 489-500	8.4	11
280	Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. <i>Haematologica</i> , 2017 , 102, 282-294	6.6	48
279	Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. <i>European Heart Journal</i> , 2017 , 38, 3070-3078	9.5	215
278	Antiviral activity of formyl peptide receptor 2 antagonists against influenza viruses. <i>Antiviral Research</i> , 2017 , 143, 252-261	10.8	14
277	Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk. <i>Scientific Reports</i> , 2017 , 7, 45507	4.9	10
276	Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features. <i>Haematologica</i> , 2017 , 102, 1006-1016	6.6	23
275	Hematopoietic stem cell transplantation for the treatment of leukocyte adhesion deficiency type III. <i>Pediatrics and Neonatology</i> , 2017 , 58, 560-561	1.8	3
274	Phenotype analysis and clinical management in a large family with a novel truncating mutation in , the CalDAG-GEFI encoding gene. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017 , 1, 128-133	5.1	14
273	Expanded repertoire of variants responsible for platelet dysfunction and severe bleeding. <i>Blood</i> , 2017 , 130, 1026-1030	2.2	32
272	Genetic risk factors for venous thrombosis in women using combined oral contraceptives: update of the PILGRIM study. <i>Clinical Genetics</i> , 2017 , 91, 131-136	4	5
271	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 2560-2570	5	32
270	Peripartum bleeding management in a patient with CalDAG-GEFI deficiency. <i>Haemophilia</i> , 2017 , 23, e533-e535	3.5	5
269	E-storage pool disease: an underestimated cause of unexplained bleeding. <i>Hematologie</i> , 2017 , 23, 243-254	3	

268	FPR2: A Novel Promising Target for the Treatment of Influenza. <i>Frontiers in Microbiology</i> , 2017 , 8, 1719	5.7	16
267	Alterations of the Platelet Procoagulant or Fibrinolytic Functions 2017 , 937-949		
266	Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome. <i>Cerebrovascular Diseases</i> , 2016 , 42, 404-414	3.2	13
265	Bantitrypsin Pittsburgh and plasmin-mediated proteolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 2023-2026	15.4	2
264	Early matrix metalloproteinase-9 concentration in the first 48 h after aneurysmal subarachnoid haemorrhage predicts delayed cerebral ischaemia: An observational study. <i>European Journal of Anaesthesiology</i> , 2016 , 33, 662-9	2.3	14
263	Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study. <i>Platelets</i> , 2016 , 27, 791-795	3.6	1
262	Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. <i>Orphanet Journal of Rare Diseases</i> , 2016 , 11, 49	4.2	59
261	Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia. <i>Platelets</i> , 2016 , 27, 828-829	3.6	12
260	Hysteresis-like binding of coagulation factors X/Xa to procoagulant activated platelets and phospholipids results from multistep association and membrane-dependent multimerization. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2016 , 1858, 1216-27	3.8	16
259	Immediate Postnatal Overfeeding in Rats Programs Aortic Wall Structure Alterations and Metalloproteinases Dysregulation in Adulthood. <i>American Journal of Hypertension</i> , 2016 , 29, 719-26	2.3	4
258	Phenotype Analysis and Clinical Management in a Large Family with a Novel Truncating Mutation in RASGRP2, the Caldag-GEFI Encoding Gene. <i>Blood</i> , 2016 , 128, 3713-3713	2.2	1
257	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 844-55	7	26
256	Risk factors for venous thromboembolism in women under combined oral contraceptive. The PILL Genetic Risk Monitoring (PILGRIM) Study. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 135-42	7	27
255	The first intracellular loop of GLUT4 contains a retention motif. <i>Journal of Cell Science</i> , 2016 , 129, 2273-843	9.3	1
254	Formyl Peptide Receptor 2 Plays a Deleterious Role During Influenza A Virus Infections. <i>Journal of Infectious Diseases</i> , 2016 , 214, 237-47	7	27
253	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. <i>Blood</i> , 2016 , 127, 2791-803	2.2	135
252	Chronic kidney disease has a significant impact on platelet inhibition of new P2Y12 inhibitors. <i>International Journal of Cardiology</i> , 2015 , 184, 428-430	3.2	6
251	Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. <i>International Journal of Obesity</i> , 2015 , 39, 480-7	5.5	63

250	CD28 deletion improves obesity-induced liver steatosis but increases adiposity in mice. <i>International Journal of Obesity</i> , 2015 , 39, 977-85	5.5	11
249	Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers. <i>Pharmacogenomics</i> , 2015 , 16, 459-69	2.6	
248	Gray platelet syndrome can mimic autoimmune lymphoproliferative syndrome. <i>Blood</i> , 2015 , 126, 1967-9	2.2	11
247	Expanding the Mutation Spectrum Affecting α IIb β Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort. <i>Human Mutation</i> , 2015 , 36, 548-61	4.7	52
246	Multilevel systems biology modeling characterized the atheroprotective efficiencies of modified dairy fats in a hamster model. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015 , 309, H935-45	5.2	9
245	The Transcriptional Effects of PCB118 and PCB153 on the Liver, Adipose Tissue, Muscle and Colon of Mice: Highlighting of Glut4 and Lipin1 as Main Target Genes for PCB Induced Metabolic Disorders. <i>PLoS ONE</i> , 2015 , 10, e0128847	3.7	16
244	Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. <i>American Journal of Cardiology</i> , 2014 , 113, 54-9	3	26
243	Spectrum of the mutations in Bernard-Soulier syndrome. <i>Human Mutation</i> , 2014 , 35, 1033-45	4.7	98
242	Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. <i>Journal of Experimental Medicine</i> , 2014 , 211, 1349-62	16.6	100
241	Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014 , 176, 1184-5	3.2	9
240	Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. <i>International Journal of Cardiology</i> , 2014 , 176, 1200-2	3.2	15
239	Reply: P2Y12-Based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 108	5	
238	Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. <i>International Journal of Cardiology Heart & Vessels</i> , 2014 , 4, 188-192		3
237	A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential. <i>Blood</i> , 2014 , 123, 777-85	2.2	14
236	Pathophysiology of inherited platelet disorders. <i>Hematologie</i> , 2014 , 20, 20-35	0	3
235	Pathophysiology of inherited platelet disorders. <i>Sang Thrombose Vaisseaux</i> , 2014 , 26, 300-316	3	
234	Efficacy of terutroban in preventing delayed cerebral ischemia after subarachnoid haemorrhage: a functional isotope imaging study on a rat model. <i>European Journal of Anaesthesiology</i> , 2014 , 31, 109	2.3	
233	Systemic inhibition and liver-specific over-expression of PAI-1 failed to improve survival in all-inclusive populations or homogenous cohorts of CLP mice. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 958-69	15.4	7

232	Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles-Nlmes prediction model. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 138-146	15.4	14
231	Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: the SAFE-ES study. <i>Annales De Cardiologie Et DLangeiologie</i> , 2014 , 63, 222-7	0.5	7
230	Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014 , 172, e1-2	3.2	12
229	First case of a humanRASGRP2mutation affecting Rap1 activation in platelets and causing severe bleeding.. <i>Journal of Cell Biology</i> , 2014 , 206, 206101A111	7.3	
228	Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 854-63	5	58
227	Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison. <i>International Journal of Cardiology</i> , 2013 , 170, e21-2	3.2	23
226	Predictors of long-term high on-treatment platelet reactivity in clopidogrel-treated patients undergoing coronary stenting for acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013 , 168, 1565-6	3.2	2
225	Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. <i>International Journal of Cardiology</i> , 2013 , 168, 523-8	3.2	20
224	Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013 , 168, 568-9	3.2	45
223	Procoagulant platelets form an α granule protein-covered "cap" on their surface that promotes their attachment to aggregates. <i>Journal of Biological Chemistry</i> , 2013 , 288, 29621-32	5.4	59
222	Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. <i>International Journal of Cardiology</i> , 2013 , 168, 5004-5	3.2	15
221	Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013 , 168, 2988-9	3.2	5
220	Palmitoylation of TNF alpha is involved in the regulation of TNF receptor 1 signalling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013 , 1833, 602-12	4.9	29
219	Prasugrel monitoring and bleeding in real world patients. <i>American Journal of Cardiology</i> , 2013 , 111, 38-44	3	37
218	Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. <i>American Journal of Cardiology</i> , 2013 , 111, 985-90	3	51
217	Effectiveness of switching hyper responders from prasugrel to clopidogrel after acute coronary syndrome: the POBA SWITCH study. <i>European Heart Journal</i> , 2013 , 34, P4883-P4883	9.5	
216	Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (Predictor Of Bleedings with Antiplatelet drugs). <i>European Heart Journal</i> , 2013 , 34, 4528-4528	9.5	
215	Microparticle increase in severe obesity: not related to metabolic syndrome and unchanged after massive weight loss. <i>Obesity</i> , 2013 , 21, 2236-43	8	81

214	ANKRD26-related thrombocytopenia and myeloid malignancies. <i>Blood</i> , 2013 , 122, 1987-9	2.2	110
213	Impact of obesity on response to thienopyridine and bleeding risk in patients treated after acute coronary syndrome by clopidogrel or prasugrel. <i>European Heart Journal</i> , 2013 , 34, P4878-P4878	9.5	
212	Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 669-80	7	81
211	Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. <i>Blood</i> , 2012 , 120, 2708-18	2.2	75
210	Epicardial fat volume is associated with coronary microvascular response in healthy subjects: a pilot study. <i>Obesity</i> , 2012 , 20, 1200-5	8	18
209	ABO blood group and von Willebrand factor levels partially explained the incomplete penetrance of congenital thrombophilia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 2021-8	9.4	18
208	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. <i>Thrombosis Research</i> , 2012 , 130, 70-4	8.2	9
207	Two types of procoagulant platelets are formed upon physiological activation and are controlled by integrin (IIb)(B). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 2475-83	9.4	34
206	An evaluation of the effects of <i>Lactobacillus ingluviei</i> on body weight, the intestinal microbiome and metabolism in mice. <i>Microbial Pathogenesis</i> , 2012 , 52, 61-8	3.8	47
205	Endocytosis and intracellular processing of platelet microparticles by brain endothelial cells. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 1731-8	5.6	64
204	Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. <i>American Heart Journal</i> , 2012 , 164, 327-33	4.9	8
203	Effects of bariatric surgery on cardiac ectopic fat: lesser decrease in epicardial fat compared to visceral fat loss and no change in myocardial triglyceride content. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1381-9	15.1	133
202	CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 1280-7	5	81
201	In vivo assessment of murine elastase-induced abdominal aortic aneurysm with high resolution magnetic resonance imaging. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012 , 44, 475-81	2.3	9
200	Recent advances in the pharmacogenetics of clopidogrel. <i>Human Genetics</i> , 2012 , 131, 653-64	6.3	25
199	Diet modulates endogenous thrombin generation, a biological estimate of thrombosis risk, independently of the metabolic status. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 2394-404	9.4	25
198	Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. <i>International Journal of Obesity</i> , 2012 , 36, 422-30	5.5	67
197	Caution in interpreting results from imputation analysis when linkage disequilibrium extends over a large distance: a case study on venous thrombosis. <i>PLoS ONE</i> , 2012 , 7, e38538	3.7	16

196	The plasminogen activation system modulates differently adipogenesis and myogenesis of embryonic stem cells. <i>PLoS ONE</i> , 2012 , 7, e49065	3.7	9
195	Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. <i>Nature Genetics</i> , 2011 , 43, 735-7	36.3	224
194	Paraoxonase-1 and clopidogrel efficacy. <i>Nature Medicine</i> , 2011 , 17, 1039; author reply 1042-4	50.5	24
193	Évaluation de l'exposition d'adipocytes humains sous-cutanés en culture aux acides linoléiques conjugués par une approche multi-omique. <i>Oleagineux Corps Gras Lipides</i> , 2011 , 18, 365-371		
192	Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 416-22	7	22
191	Platelets alter gene expression profile in human brain endothelial cells in an in vitro model of cerebral malaria. <i>PLoS ONE</i> , 2011 , 6, e19651	3.7	31
190	KNG1 Ile581Thr and susceptibility to venous thrombosis. <i>Blood</i> , 2011 , 117, 3692-4	2.2	43
189	CD11b+ leukocyte microparticles are associated with high-risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 1870-3	15.4	14
188	Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome. <i>American Journal of Cardiology</i> , 2011 , 108, 760-5	3	35
187	Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. <i>American Journal of Cardiology</i> , 2011 , 108, 1411-6	3	17
186	High prevalence of laminopathies among patients with metabolic syndrome. <i>Human Molecular Genetics</i> , 2011 , 20, 3779-86	5.6	43
185	High residual platelet reactivity and thrombotic events. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 2561; author reply 2561-2	27.4	1
184	Plasminogen activator inhibitor 1 is an intracellular inhibitor of furin proprotein convertase. <i>Journal of Cell Science</i> , 2011 , 124, 1224-30	5.3	31
183	A novel leukocyte adhesion deficiency III variant: kindlin-3 deficiency results in integrin- and nonintegrin-related defects in different steps of leukocyte adhesion. <i>Journal of Immunology</i> , 2011 , 186, 5273-83	5.3	49
182	p38 mitogen activated protein kinase controls two successive-steps during the early mesodermal commitment of embryonic stem cells. <i>Stem Cells and Development</i> , 2011 , 20, 1233-46	4.4	24
181	Circulating matrix metalloproteinases in infective endocarditis: a possible marker of the embolic risk. <i>PLoS ONE</i> , 2011 , 6, e18830	3.7	14
180	Genetics of venous thrombosis: insights from a new genome wide association study. <i>PLoS ONE</i> , 2011 , 6, e25581	3.7	105
179	Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 774-9	7	8

178	Down-regulation of tissue inhibitor of metalloproteinase-3 (TIMP-3) expression is necessary for adipocyte differentiation. <i>Journal of Biological Chemistry</i> , 2010 , 285, 6508-14	5.4	32
177	Secretory type II phospholipase A2 is produced and secreted by epicardial adipose tissue and overexpressed in patients with coronary artery disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 963-7	5.6	76
176	Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. <i>Archives of Cardiovascular Diseases</i> , 2010 , 103, 39-45	2.7	48
175	Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder: shifting from antiplatelet resistance to bleeding risk assessment?. <i>International Journal of Cardiology</i> , 2010 , 138, 212-3	3.2	9
174	Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation). <i>Thrombosis Research</i> , 2010 , 126, e397-9	8.2	3
173	Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. <i>Thrombosis Research</i> , 2010 , 126, e400-2	8.2	23
172	Glycemic control and clopidogrel response. <i>American Heart Journal</i> , 2010 , 159, e35	4.9	
171	Anticoagulant and antithrombotic properties of platelet protease nexin-1. <i>Blood</i> , 2010 , 115, 97-106	2.2	56
170	C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. <i>Blood</i> , 2010 , 115, 4644-50	2.2	50
169	A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1. <i>American Journal of Human Genetics</i> , 2010 , 86, 592-5	11	51
168	A Follow-Up Study of a Genome-wide Association Scan Identifies a Susceptibility Locus for Venous Thrombosis on Chromosome 6p24.1. <i>American Journal of Human Genetics</i> , 2010 , 86, 655	11	78
167	Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study. <i>Journal of Molecular Medicine</i> , 2010 , 88, 193-201	5.5	5
166	Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 942-9	15.4	11
165	Plasminogen activator inhibitor type-1 is an independent marker of metabolic disorders in young adults born small for gestational age. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 2608-13	15.4	9
164	A multi-stage multi-design strategy provides strong evidence that the BAI3 locus is associated with early-onset venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 2671-9	15.4	35
163	Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. <i>Blood</i> , 2009 , 113, 5298-303	2.2	235
162	Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium. <i>FASEB Journal</i> , 2009 , 23, 3449-58	0.9	91
161	Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. <i>American Journal of Cardiology</i> , 2009 , 104, 1078-82	3	61

160	The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. <i>Diabetologia</i> , 2009 , 52, 1152-63	10.3	93
159	Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. <i>Obesity</i> , 2009 , 17, 2121-6	8	90
158	Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 49-57	15.4	156
157	The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 1409-11	15.4	102
156	Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 1939-41	15.4	22
155	Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. <i>Thrombosis Research</i> , 2009 , 123, 597-603	8.2	65
154	Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. <i>American Heart Journal</i> , 2009 , 157, 889-93	4.9	66
153	Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1149-53	15.1	182
152	Platelet-endothelial cell interactions in cerebral malaria: the end of a cordial understanding. <i>Thrombosis and Haemostasis</i> , 2009 , 102, 1093-102	7	55
151	Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?. <i>EuroIntervention</i> , 2009 , 5, 325-9	3.1	120
150	Epicardial adipose tissue extent: relationship with age, body fat distribution, and coronaropathy. <i>Obesity</i> , 2008 , 16, 2424-30	8	110
149	Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 1494-9	15.4	35
148	Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 1975-7	15.4	11
147	Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. <i>American Journal of Cardiology</i> , 2008 , 101, 1088-93	3	174
146	Adjusting clopidogrel loading doses according to vasodilator-stimulated phosphoprotein index: on time, too early, or too late?. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 790-1; author reply 791-2	15.1	2
145	Metabolic syndrome, haemostasis and thrombosis. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 995-1000	7	134
144	Tissu adipeux viscéral et thrombose: Au-delà de sa fonction hépatique, le tissu adipeux sécrète de multiples adipokines.. <i>Archives Des Maladies Du Cœur Et Des Vaisseaux - Pratique</i> , 2008 , 2008, 19-27	0	
143	Energy intake is associated with endotoxemia in apparently healthy men. <i>American Journal of Clinical Nutrition</i> , 2008 , 87, 1219-23	7	420

142	Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. <i>JACC: Cardiovascular Interventions</i> , 2008 , 1, 649-53	5	120
141	Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. <i>BMC Molecular Biology</i> , 2008 , 9, 26	4.5	102
140	Progression of atherosclerosis in ApoE-deficient mice that express distinct molecular forms of TNF-alpha. <i>Journal of Pathology</i> , 2008 , 214, 574-83	9.4	36
139	HDLs activate ADAM17-dependent shedding. <i>Journal of Cellular Physiology</i> , 2008 , 214, 687-93	7	35
138	High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 282-287	7	84
137	Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 949-954	7	75
136	Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 212-217	7	62
135	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 838-843	7	181
134	Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5, 475-82	15.4	55
133	Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5, 2467-75	15.4	12
132	Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2007 , 100, 1199-206	3	96
131	C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. <i>Diabetologia</i> , 2007 , 50, 1267-76	10.3	278
130	Effect of sleep apnea syndrome on the circadian profile of cortisol in obese men. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007 , 293, E466-74	6	38
129	Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 2250-7	9.4	57
128	Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. <i>Current Opinion in Lipidology</i> , 2007 , 18, 240-5	4.4	142
127	Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. <i>Thrombosis Research</i> , 2007 , 120, 893-9	8.2	69
126	Metabolic endotoxemia initiates obesity and insulin resistance. <i>Diabetes</i> , 2007 , 56, 1761-72	0.9	3888
125	Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?. <i>Immunobiology</i> , 2007 , 212, 557-65	3.4	25

124	MRI follow-up of TNF-dependent differential progression of atherosclerotic wall-thickening in mouse aortic arch from early to advanced stages. <i>Atherosclerosis</i> , 2007 , 195, e93-9	3.1	16
123	Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. <i>American Journal of Pathology</i> , 2007 , 171, 1713-23	5.8	85
122	Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 62-66	7	9
121	Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 212-7	7	2
120	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 838-43	7	23
119	Modulation of adipose tissue development by pharmacological inhibition of PAI-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 2209-15	9.4	69
118	Expression of adrenomedullin in adipose tissue of lean and obese women. <i>European Journal of Endocrinology</i> , 2006 , 155, 177-85	6.5	24
117	PAI-1 and the metabolic syndrome: links, causes, and consequences. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 2200-7	9.4	271
116	The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. <i>Atherosclerosis</i> , 2006 , 187, 82-91	3.1	69
115	Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 1339-45	15.1	289
114	Lipides peroxyd et réaction immuno-inflammatoire dans l'athérosclérose. <i>Oleagineux Corps Gras Lipides</i> , 2006 , 13, 337-342		
113	Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. <i>Blood</i> , 2006 , 108, 1562-8	2.2	35
112	t-PA antigen. <i>EMC - Biologie Médicale</i> , 2006 , 1, 1-3		
111	High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 542-9	15.4	320
110	Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006 , 291, E995-E1002	6	45
109	Tiplaxtinin impairs nutritionally induced obesity in mice. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 731-737	7	11
108	Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. <i>Atherosclerosis</i> , 2005 , 179, 317-23	3.1	22
107	TAFI levels in patients with acute myocardial infarction treated with thrombolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 395-7	15.4	3

106	On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 1174-9	15.4	54
105	Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. <i>British Journal of Haematology</i> , 2005 , 128, 91-9	4.5	68
104	Heterogeneity of anti-beta2-glycoprotein I antibodies. A factor of variability in test results. <i>Thrombosis and Haemostasis</i> , 2005 , 93, 80-7	7	13
103	Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. <i>Thrombosis and Haemostasis</i> , 2005 , 94, 373-9	7	27
102	PPAR δ deficiency does not modify age dependency but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance. <i>Thrombosis and Haemostasis</i> , 2004 , 91, 1051-1052	7	3
101	Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. <i>Circulation</i> , 2004 , 109, 1343-8	16.7	177
100	Beta-thalassaemia-87 C-->G: relationship of the Hb F modulation and polymorphisms in compound heterozygous patients. <i>British Journal of Haematology</i> , 2004 , 126, 743-9	4.5	6
99	A 13 base pair deletion in the GPIIb/IIIa gene in a second unrelated Bernard-Soulier family due to slipped mispairing between direct repeats. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1663-5	15.4	6
98	Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. <i>Journal of Internal Medicine</i> , 2004 , 255, 448-56	10.8	45
97	Relations between hemostatic variables, insulin resistance and inflammation. <i>The Hematology Journal</i> , 2004 , 5 Suppl 3, S15-9		2
96	Development of a genotype 325-specific proCPU/TAFI ELISA. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 1122-7	9.4	76
95	Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 1262-8	9.4	144
94	Adipose tissue and atherothrombosis. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003 , 33, 290-7		49
93	Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 791-7	15.4	50
92	Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 1575-9	15.4	277
91	The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 2322-9	15.4	47
90	Expression of the mRNAs coding for the glucocorticoid receptor isoforms in obesity. <i>Obesity</i> , 2003 , 11, 925-9		33
89	A novel missense mutation shows that GPIIb/IIIa has a dual role in controlling the processing and stability of the platelet GPIb-IX adhesion receptor. <i>Biochemistry</i> , 2003 , 42, 4452-62	3.2	23

88	Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 78-84	9.4	81
87	Les statines en thérapeutique cardiovasculaire. <i>Medecine/Sciences</i> , 2002 , 18, 1257-1265		
86	Relationships between Fibrinolytic and Inflammatory Parameters in Human Adipose Tissue: Strong Contribution of TNF Receptors to PAI-1 Levels. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 481-487	7	30
85	Anti-phospholipid/cofactor antibodies in three cases of persistent polyclonal B lymphocytosis. <i>British Journal of Haematology</i> , 2002 , 119, 875-6	4.5	2
84	Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 173-8	9.4	156
83	Expression of the mRNA coding for 11 β -hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 2701-5	5.6	202
82	The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002 , 32, 269-73		49
81	Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 867-73	9.4	132
80	Expression of the mRNA Coding for 11 β -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue from Obese Patients: An in Situ Hybridization Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 2701-2705	5.6	161
79	Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. <i>Blood</i> , 2001 , 97, 2053-8	2.2	133
78	Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. <i>Diabetologia</i> , 2001 , 44, 2025-31	10.3	106
77	Antibodies to Phosphatidylethanolamine as the only Antiphospholipid Antibodies Found in Patients with Unexplained Thromboses. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 800-805	7	51
76	Adipose Tissue Expression of Gelatinases in Mouse Models of Obesity. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 1111-1116	7	54
75	Système fibrinolytique, métalloproteases et pathologie vasculaire.. <i>Medecine/Sciences</i> , 2001 , 17, 170		4
74	Plasma TAFI Antigen Variations in Healthy Subjects. <i>Thrombosis and Haemostasis</i> , 2000 , 83, 902-905	7	89
73	Formation, inhibition and clearance of plasmin in vivo. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000 , 30, 204-18		11
72	The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 1387-91	9.4	48
71	Fat cell function and fibrinolysis. <i>Hormone and Metabolic Research</i> , 2000 , 32, 504-8	3.1	40

70	Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. <i>Diabetes</i> , 2000 , 49, 1374-80	0.9	282
69	Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 2156-61	9.4	79
68	Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 1150-4	9.4	105
67	Rapid Detection of Factor XIII Val34Leu by Allele Specific PCR. <i>Thrombosis and Haemostasis</i> , 1999 , 81, 463-463	7	10
66	PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999 , 19, 1361-5	9.4	84
65	Fibrinolytic function and coronary risk. <i>Current Cardiology Reports</i> , 1999 , 1, 119-24	4.2	27
64	Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. <i>Journal of Infectious Diseases</i> , 1999 , 180, 2074-6	7	97
63	Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. <i>Diabetes</i> , 1999 , 48, 890-5	0.9	103
62	Regulation of PAI-1 in obesity and insulin resistance. <i>Atherosclerosis</i> , 1999 , 144, 14	3.1	
61	PAI-1, Obesity, and Insulin Resistance 1999 , 317-332		4
60	Relationship of Plasminogen Activator Inhibitor-1 Levels following Thrombolytic Therapy with rt-PA as Compared to Streptokinase and Patency of Infarct Related Coronary Artery. <i>Thrombosis and Haemostasis</i> , 1999 , 82, 104-108	7	13
59	Regulation of Fibrinolysis in the Development of Atherothrombosis: Role of Adipose Tissue. <i>Thrombosis and Haemostasis</i> , 1999 , 82, 832-836	7	32
58	Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. <i>International Journal of Obesity</i> , 1998 , 22, 312-7	5.5	79
57	Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998 , 18, 84-91	9.4	115
56	A Three-generation Family Presenting Five Cases of Homozygosity for the 20210 G to A Prothrombin Variant. <i>Thrombosis and Haemostasis</i> , 1998 , 80, 859-860	7	12
55	PAI-1 and the Risk of Cardiovascular Disease. <i>Medical Science Symposia Series</i> , 1998 , 85-92		4
54	Variables of the fibrinolytic system: risk indicators for CHD. <i>Fibrinolysis and Proteolysis</i> , 1997 , 11, 47-49		1
53	Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 851-8	9.4	66

52	Intracellular calcium mobilization suppresses the TNF-alpha-stimulated synthesis of PAI-1 in human endothelial cells. Indications that calcium acts at a translational level. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 1550-60	9.4	18
51	Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. <i>Diabetes</i> , 1997 , 46, 860-867	0.9	141
50	PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 656-660	7	267
49	Acquired Protein S Deficiency, Likely due to Anti-PS Autoantibodies, following a Thrombotic Event in a Patient with a Systemic Lupus erythematosus. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 1416-1417	7	8
48	Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937. <i>Blood</i> , 1996 , 87, 162-173	2.2	25
47	Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. <i>Blood</i> , 1996 , 88, 410-416	2.2	206
46	Iloprost and salvage of a free flap. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 1996 , 49, 245-8		20
45	Fibrinolysis and risk of coronary artery disease. <i>Fibrinolysis</i> , 1996 , 10, 127-136		27
44	Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. <i>Annals of Medicine</i> , 1996 , 28, 371-80	1.5	125
43	Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. <i>Circulation</i> , 1996 , 94, 2057-63	16.7	344
42	New Direct Assay of Free Protein S Antigen Applied to Diagnosis of Protein S Deficiency. <i>Thrombosis and Haemostasis</i> , 1996 , 75, 283-285	7	18
41	Purpura Fulminans in a Patient Homozygous for a Mutation in the Protein C Gene - Prenatal Diagnosis in a Subsequent Pregnancy. <i>Thrombosis and Haemostasis</i> , 1996 , 75, 525-526	7	5
40	Fibrinolytic and inflammatory processes in pleural effusions. <i>European Respiratory Journal</i> , 1995 , 8, 1352-1356	16.6	89
39	Up-regulation of PAI-1 synthesis by insulin and proinsulin in HEP G2 cells but not in endothelial cells. <i>Fibrinolysis</i> , 1995 , 9, 237-242		21
38	Pathophysiology of fibrinolysis. <i>Best Practice and Research: Clinical Haematology</i> , 1995 , 8, 329-43		19
37	Plasma Plasminogen Activator Inhibitor Activity in Rats with Nutritionally Induced Insulin Resistance. <i>Thrombosis and Haemostasis</i> , 1995 , 74, 806-807	7	3
36	Relation between Plasma PAI Activity and Adipsin Levels. <i>Thrombosis and Haemostasis</i> , 1995 , 74, 1200-1202		11
35	Up-Regulated Expression of Plasminogen Activator Inhibitor-1 in Hep G2 Cells: Interrelationship between Insulin and Insulin-Like Growth Factor 1. <i>Thrombosis and Haemostasis</i> , 1995 , 73, 268-274	7	15

34	Intraperitoneal insulin administration does not modify plasminogen activator inhibitor 1 levels in IDDM patients. <i>Diabetes Care</i> , 1994 , 17, 941-2	14.6	5
33	Cutaneous Necrosis Associated with Acquired Severe Protein S Deficiency. <i>Thrombosis and Haemostasis</i> , 1994 , 71, 396-396	7	4
32	Plasminogen Activator Inhibitor-1 Expression in Human Liver and Healthy or Atherosclerotic Vessel Walls. <i>Thrombosis and Haemostasis</i> , 1994 , 72, 044-053	7	77
31	Detection of Plasminogen Activator Inhibitor-1 (PAI-1) mRNA in Human Megakaryocytes by In Situ Hybridization. <i>Thrombosis and Haemostasis</i> , 1994 , 72, 931-936	7	19
30	Plasminogen activator inhibitor activity in various types of endogenous hypertriglyceridemia. <i>Fibrinolysis</i> , 1993 , 7, 171-176		25
29	Granulocyte-endothelium initial adhesion. Analysis of transient binding events mediated by E-selectin in a laminar shear flow. <i>Biophysical Journal</i> , 1993 , 64, 1922-33	2.9	161
28	Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. <i>Journal of Clinical Investigation</i> , 1993 , 91, 2185-93	15.9	59
27	Plasminogen Activator Inhibitor 1 and Atherothrombosis. <i>Thrombosis and Haemostasis</i> , 1993 , 70, 138-143		134
26	Fibrinolysis in insulin dependent diabetic patients with or without nephropathy. <i>Fibrinolysis</i> , 1992 , 6, 105-109		21
25	Daytime Fluctuations of Plasminogen Activator Inhibitor 1 (PAI-1) in Populations with High PAI-1 Levels. <i>Thrombosis and Haemostasis</i> , 1992 , 67, 076-082	7	27
24	Lupus anticoagulant in silica-induced scleroderma. <i>Clinical Rheumatology</i> , 1992 , 11, 444-5	3.9	
23	Venous Occlusion Does Not Induce the Release of Thrombomodulin from Endothelial Cells in Patients with Thromboembolic Disease. <i>Thrombosis and Haemostasis</i> , 1992 , 68, 483-484	7	3
22	Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. <i>Diabetologia</i> , 1991 , 34, 457-62	10.3	486
21	Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1991 , 11, 1821-9		85
20	Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. <i>Thrombosis Research</i> , 1991 , 62, 275-85	8.2	15
19	Characterization of Epitheloid Cells from Human Omentum: Comparison with Endothelial Cells from Umbilical Veins. <i>Thrombosis and Haemostasis</i> , 1991 , 66, 361-367	7	19
18	Effect of low density lipoproteins on secretion of plasminogen activator inhibitor-1 (PAI-1) by human endothelial cells and hepatoma cells. <i>Fibrinolysis</i> , 1990 , 4, 82-83		14
17	The determination of functional plasminogen activator inhibitors (PAI) based on the inhibition of urokinase: PAI normal range and circadian variations in healthy donors; Comparison with other methods. <i>Fibrinolysis</i> , 1990 , 4, 177-181		6

16	Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. <i>Thrombosis Research</i> , 1990 , 60, 509-16	8.2	44
15	Lupus anticoagulants and antiphospholipid antibodies: comparison of clotting tests with an immunological assay. <i>Thrombosis Research</i> , 1990 , 60, 181-3	8.2	1
14	The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. <i>Clinica Chimica Acta</i> , 1990 , 188, 119-27	6.2	27
13	Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells. <i>Infection and Immunity</i> , 1990 , 58, 2459-63	3.7	25
12	Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. <i>Arteriosclerosis (Dallas, Tex.)</i> , 1989 , 9, 362-7		187
11	Potentialiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator. <i>Seminars in Thrombosis and Hemostasis</i> , 1989 , 15, 390-4	5.3	2
10	Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. <i>Metabolism: Clinical and Experimental</i> , 1989 , 38, 913-5	12.7	120
9	Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). <i>FEBS Journal</i> , 1988 , 175, 531-40		65
8	Relevance of Free tPA Assay Following Venous Occlusion in Patients with Venous Thromboembolic Disease. <i>Thrombosis and Haemostasis</i> , 1988 , 59, 346-347	7	5
7	RELEVANCE OF FREE t-PA ASSAY FOLLOWING VENOUS OCCLUSION IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE 1987 , 58, 1627		
6	EFFECT OF DIFFERENT HEPARINS ON THROMBOLYSIS WITH t-PA AND scu-PA IN RABBITS WITH EXPERIMENTAL THROMBOSIS 1987 , 58, 0993		
5	Potentialiation by Heparin Fragments of Thrombolysis Induced with Human Tissue-Type Plasminogen Activator or Human Single-Chain Urokinase-Type Plasminogen Activator. <i>Thrombosis and Haemostasis</i> , 1987 , 58, 947-950	7	33
4	Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis. <i>Thrombosis and Haemostasis</i> , 1987 , 57, 067-072	7	281
3	Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects. <i>Thrombosis and Haemostasis</i> , 1987 , 57, 326-328	7	119
2	Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. <i>Metabolism: Clinical and Experimental</i> , 1986 , 35, 250-3	12.7	393
1	Mutations in CalDAG-GEFI Lead to Striatal Signaling Deficits and Psychomotor Symptoms in Multiple Species Including Human		2